Lindsay Bealor Greenleaf talks to Fierce Healthcare about the Trump administration’s plan to reform the prescription drug supply chain
Lindsay Bealor Greenleaf, Director at ADVI, told Fierce Healthcare that some of the biggest provisions include changes to pharmacy benefit managers. The administration floated the idea of considering fiduciary status for PBMs and determining whether the rebates they seek out create an incentive to favor higher list prices... Greenleaf said changes to this status would likely not happen in the near future, but it does highlight Trump and HHS Secretary Alex Azar's focus on getting rid of the middleman.
[el-text]
Written by Mike Stankiewicz
***excerpt***
Lindsay Bealor Greenleaf, Director at ADVI, told Fierce Healthcare that some of the biggest provisions include changes to pharmacy benefit managers. The administration floated the idea of considering fiduciary status for PBMs and determining whether the rebates they seek out create an incentive to favor higher list prices… Greenleaf said changes to this status would likely not happen in the near future, but it does highlight Trump and HHS Secretary Alex Azar’s focus on getting rid of the middleman.
***end excerpt***
***
[/el-text]
View full article here
Reach out
Own your edge
We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.